CBCS infrastructure selected to EU research infrastructure
EU-OPENSCREEN integrates high-capacity chemical biology screening platforms throughout Europe. From 1 July this year, Sweden expands the circle of platform member countries from nine to ten countries. Chemical Biology Consortium Sweden, CBCS, at Umeå University was selected as one of the Swedish partner sites.
Text: Ingrid Söderbergh
CBCS offers expertise, support and experimental resources in assay development, computational chemistry, cheminformatics, small molecule development and screening, medicinal/synthetic chemistry and target ID
ImageMikael Wallerstedt, ej friköpta
The membership will also open for European researchers to access the expertise built up within CBCS.
Sweden has been an important partner in EU-OPENSCREEN since the preparatory phase over the past ten years. From this year onwards, Sweden becomes a full member.
“We are delighted that Sweden becomes a member of our research infrastructure. Our new partners at Karolinska Institutet and Umeå University have an impressive track record in molecular medicine. We are proud to have them on board to support our growing number of scientific collaborations”, says Wolfgang Fecke, Director of EU-OPENSCREEN.
KI and Umeå University selected
The representing entity is the Swedish Research Council. Sweden will be represented in the Assembly of Members by Helena Berglund (VR) and Professor Fredrik Almqvist (Umeå University).
Two official partner sites in Sweden have successfully passed the partner site selection procedure and will complement the EU-OPENSCREEN consortium: the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet (CBCS-KI) in Stockholm and the Department of Chemistry at Umeå University (CBCS-UmU).
CBCS Umeå is situated at the Department of Chemistry and has dedicated facilities for assay development, high throughput and high content screening, synthetic chemistry facilities and medicinal chemistry support. CBCS Umeå also has advanced cell biology and infection labs (BSL-2 level) and long experience of screening with infection disease models. It has significant expertise with different infection models, co-culturing, organoid culturing, as well as whole-organism screening and microbiology screens.
ImageMikael Wallerstedt SciLifeLab
Screening and medicinal chemistry support
As one of the two founding nodes in CBCS, the CBCS Umeå chemistry team has gained extensive experiences in screening hit evaluations, lead identification and optimization, and structure-based design as well as hit evaluation from cell based phenotypic screens. The team also has experience in probe development for mechanism of action (MoA) elucidations.
As a new EU-OPENSCREEN partner site, CBCS Umeå will provide screening and medicinal chemistry support.
”CBCS has assisted Swedish researchers in the field for over a decade and the membership in EU-OPENSCREEN will now open new avenues for Swedish researchers. The membership will also open for European researchers to access the expertise built up within CBCS”, says Erik Chorell Associate Professor, Director, Chemical Biology Consortium Sweden at Umeå University.